In most human tumours investigated so far, both ET receptor subtypes have been identified (Nelson et al, 2003), although pharmacological manipulation of the endothelin axis for cancer therapy has concentrated on the potential for ETA antagonists (Nelson, 2001; Nelson et al, 2003; Sonveaux et al, 2004). Here, EDNRA is linked to neoplasm.